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SUMMARY
This systematic review aimed at estimating chronic hepatitis B (HBV) and C virus (HCV)
prevalence in the European Union (EU) and Economic Area (EEA) countries in the general
population, blood donors and pregnant women. We searched PubMed©, Embase© and Cochrane
Library databases for reports on HBV and HCV prevalence in the general population and
pregnant women in EU/EEA countries published between 2005 and 2015. Council of Europe
data were used for HBV and HCV blood donor prevalence. HBV general population estimates
were available for 13 countries, ranging from 0·1% to 4·4%. HCV general population estimates
were available for 13 countries, ranging from 0·1% to 5·9%. Based on general population and
blood donor estimates, the overall HBV prevalence in the EU/EEA is estimated to be 0·9%
(95% CI 0·7–1·2), corresponding to almost 4·7 million HBsAg-positive cases; and the overall
HCV prevalence to be 1·1% (95% CI 0·9–1·4), equalling 5·6 million anti-HCV-positive cases. We
found wide variation in HCV and HBV prevalence across EU/EEA countries for which estimates
were available, as well as variability between groups often considered a proxy for the general
population. Prevalence estimates are essential to inform policymaking and public health practice.
Comparing to other regions globally, HBV and HCV prevalence in the EU/EEA is low.
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INTRODUCTION
Both hepatitis B (HBV) and C virus (HCV) affect the
liver and can cause acute and chronic hepatitis. People
with chronic HBV or HCV infection may transmit the
virus to others and are at risk of developing serious
liver disease such as cirrhosis or hepatocellular cancer
(HCC) [1, 2]. Transmission of HBV and HCV can
occur via sexual or blood–blood contact, or vertically
(mother-to-child) [3, 4]. In Europe, the high-risk
groups for acquisition of HBV include men who
have sex with men (MSM) and people who inject
drugs (PWID). The key risk groups for HCV include
PWID, people in prison and MSM.
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The risk of developing chronic HBV infection
depends on the age at which people are infected,
with 90% of infants infected at birth developing
chronic infection, compared with 1–10% of those
infected at an older age or as adults [5, 6]. Globally
248 million people were estimated to be chronically
infected with HBV in 2010 [7]. Approximately 780
000 people die each year from HBV infection, mostly
from chronic HBV infection-related sequelae such as
cirrhosis and HCC [8].
Initial infection with HCV is often asymptomatic or
mild (70–90% of cases); however, the majority of those
infected with the virus (70–80%) develop chronic
infection and, over a period of 20–30 years, 10–20%
on average will develop cirrhosis and 1–5% will
develop liver cancer [2]. An estimated 184 million peo-
ple globally have chronic HCV infection [9] and 350
000–500 000 deaths are attributable each year to
HCV-related liver diseases [8].
In 2011, the European Centre for Disease
Prevention and Control (ECDC) started enhanced
European Union (EU)-wide surveillance for HBV
and HCV, based on annual data collection from EU
and Economic Area (EEA) Member States (MS). In
2014, 22442 newly diagnosed HBV infection cases
were reported from 30 MS, a rate of 4·2 cases/100
000 population [10]. In the same year, 35 321 newly
diagnosed HCV infection cases were reported from
28 MS, a crude rate of 8·8 cases/100 000 population
in the EU/EEA [11]. However, because HBV and
HCV infections are typically asymptomatic until
advanced liver disease develops [1, 2], notiﬁcation
data are known to be incomplete and reﬂect national
screening and testing practices rather than the real
number of infections. Supplementary information in
the form of reliable and timely prevalence data is
therefore important to describe the current burden
of disease in the EU/EEA more accurately.
The recent development of more effective HBV and
HCV treatment means that elimination of chronic
viral hepatitis in Europe is now a possibility [12, 13].
However, 65–90% of infected people remain unaware
of their infection and models predict that associated
mortality will continue to increase as the current
infected population ages [12, 14, 15]. Achieving poten-
tial population health gains through treatment will
require signiﬁcant expansion of screening and treat-
ment among the most affected populations. Robust
strategic information will be of even more relevance
in view of the recently approved WHO viral hepatitis
global health sector strategy, the corresponding
European regional action plan, and its monitoring
needs [16, 17].
We updated a previous systematic review under-
taken by ECDC in 2009 [18] with the aim to assess
any changes and estimate the current prevalence of
chronic HBV and HCV infection in EU/EEA coun-
tries in the general population, blood donors and
pregnant women. As a secondary goal, we reviewed
the availability, quality and geographical coverage of
HBV and HCV prevalence data in the region in
view of designing and monitoring future prevention
and control initiatives.
METHODS
Search strategy and selection criteria
Original research articles were retrieved from
PubMed®, Embase® and Cochrane Library data-
bases in March 2015. The search strategies (Supple-
mentary Fig. S1) combined controlled (MeSH/
Emtree terms) and natural vocabulary (keywords) to
deﬁne disease-related (HBV/HCV infection), out-
come-related (prevalence) and geographic-related
(EU/EEA) search parameters. The search was limited
to records published from 1 January 2005 to 12 March
2015. Articles in all EU/EEA languages were
included. The results of the search were shared with
ECDC National Focal Points (NFP) for viral hepa-
titis in all 31 EU/EEA MS in May 2015 for review
and to validate the list of included references for
their country.
Inclusion and exclusion criteria (Supplementary
Table S2) encompassed time-related criteria including
publishing date (2005 or later); sampling timeframe
(data collection ending after 2000 or beginning from
2000 onwards); geographical coverage (EU/EEA MS
and/or any of their regions/districts) and disease-
speciﬁc markers (HBsAg/anti-HCV (and DNA/
RNA) prevalence). Only studies reporting original
data were included, although reference lists of relevant
reviews were consulted for any original articles not
captured by the literature search. Articles reporting
prevalence in the general population or pregnant
women with a sample size of <100 participants were
excluded. Articles reporting only self-reported
HBsAg/anti-HCV prevalence were also excluded.
To ensure consistent application of the inclusion
criteria, two reviewers (SHIH and AMF) independ-
ently reviewed the title and abstract of the same random
selection of retrieved articles (5%). The inclusion
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criteria were further reﬁned and a second round of
reviewing was conducted to ensure consistent applica-
tion (>95% agreement) of the criteria. Following this,
title and abstract screening for all articles continued
independently using Endnote. The full texts of all pub-
lications included after title/abstract screening were
assessed for relevance by members of the research
team where language comprehension existed (articles
in English, Dutch, French, Italian and German) or
by ECDC reviewers (other EU/EEA languages). In
case of uncertainty about in- or exclusion, the two
reviewers consulted each other and cases of disagree-
ment were resolved by consultation with a third
team member (IKV).
Deﬁnitions
Chronic HBV and HCV were deﬁned as the presence
of HBsAg and anti-HCV in serum, saliva or dry blood
spot samples, respectively. The general population
was deﬁned as people (all ages or adults only) living
in a deﬁned geographical area; patients attending
community/primary health care settings; and work-
force/speciﬁc professional groups (e.g. workplace
screening) but not healthcare workers. Pregnant
women were deﬁned as those women undergoing ante-
natal care screening, and blood donors were deﬁned as
ﬁrst-time blood donors (Supplementary Table S3).
Data extraction and quality assessment
Data extraction using a pre-deﬁned set of variables
(Supplementary Table S4) was performed simultan-
eously with full-text screening. The unit for data
extraction was ‘study’, deﬁned as a prevalence data
report on HBsAg or anti-HCV for a deﬁned popula-
tion group, in a deﬁned country, over a discrete per-
iod; one article may therefore include more than one
study. Studies published in more than one article
were extracted only once and the article with most
details about the study used as the reference.
Each included study was evaluated for risk of selec-
tion bias using a framework developed ad hoc by the
research team. Separate assessment frameworks were
developed for the general population and pregnant
women to account for differences in possible sources
of selection bias. For general population studies, the
domains age, gender, sampling method and response
rate, and geographical coverage were considered as
possible sources of selection bias (Supplementary
Table S5). For pregnant women studies, potential
selection bias sources included sampling method and
geographical coverage (Supplementary Table S6).
Points were awarded in each domain for representa-
tiveness or lower risk of bias, and a total score was cal-
culated by summing the values in each domain. This
resulted in a score between zero and six for the general
population studies and between zero and three for the
pregnant women studies. We refer to the total score as
study quality score, since a higher score indicates a
lower risk of bias. A general population estimate
was considered of high quality when it reached a
study quality score 54. A high-quality estimate of
prevalence in pregnant women was deﬁned as a
study quality score 52.
Data analysis
This review reports HBsAg and anti-HCV prevalence,
rather than a viraemic marker of HCV chronic infec-
tion, since information on HCV RNA and HBV
DNA prevalence was reported in too few studies to
conduct an analysis.
National weighted or standardized (e.g. for age
and/or sex distribution) prevalence estimates, if avail-
able (Czech Republic and Belgium for HBV), were
preferred over unweighted or crude estimates. Crude
estimates for the general population with the highest
quality (score 54) were pooled at country level,
where available, by summing cases and sample size.
Ninety-ﬁve per cent conﬁdence intervals (95% CI)
were then calculated using the Fisher’s exact method
in Microsoft Excel©. General population estimates
were reported separately for adults and children
where available. All higher quality estimates of
HBsAg and anti-HCV prevalence (score 54)
retrieved for each country for the general population
are presented in forest plots (Microsoft Excel©).
Higher quality prevalence estimates from pregnant
women studies (score 52) were also pooled where
possible (using the methodology as described above)
and separate forest plots prepared for HBV and
HCV. Prevalence maps of Europe for pooled or
single higher quality estimates were created using the
ECDC Mapping and Multi-Layer Analysis
(EMMA) tool [19].
Blood donor data
To assess the HBV and HCV prevalence among blood
donors, data from 2014 collected by the Council of
Europe were used [20]. The Council of Europe collects
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comprehensive national data on blood donors. For
countries with no data in the 2014 Council of
Europe report, the most recent data from previous
Council of Europe reports were used. No risk of
bias assessment was performed for data on blood
donors, as no data were available other than the num-
ber of ﬁrst-time blood donors and the number of infec-
tions. When data on number of cases were available,
we calculated 95% CI using the Fisher’s exact method.
The burden of chronic hepatitis B and C in the EU/EEA
In order to estimate the current burden of chronic
HBV and HCV in the EU/EEA, an algorithm com-
bining general population and blood donor data was
applied. If a pooled or single higher quality general
population prevalence crude estimate was available
for a country, this was used to determine the HBV
and HCV prevalence in that country; if a higher qual-
ity estimate was not available, lower quality general
population crude estimates were used (these were
pooled when possible); if no general population esti-
mates were available, prevalence data from blood
donors were used. To determine the total number of
chronic HBV and HCV cases in each country, total
population size (based on Eurostat 2014 data) for
each country was multiplied by the estimated HBV
and HCV prevalence in each country.
RESULTS
The literature search retrieved 9379 citations. After
title/abstract screening, 142 articles for the general
population and 50 articles for pregnant women were
included. Seventeen MS validated the search results
and/or provided additional references, adding nine
additional citations for the general population and
ﬁve for pregnant women. While all 55 full texts were
available for pregnant women, three general popula-
tion articles could not be retrieved. Following full-text
screening, 48 articles for the general population and
32 articles for pregnant women were ﬁnally included
(Fig. 1).
General population
From the 48 articles included, 53 HBsAg prevalence
estimates and 45 anti-HCV estimates were extracted.
For HBV, multiple estimates were available for 13
of 15 countries covered, with the most estimates (10)
available for Italy (Supplementary Table S7). For
HCV, more than one estimate was available for nine
countries of 16 countries covered, with most estimates
(14) again available for Italy (Supplementary
Table S8).
From the 53 prevalence HBsAg estimates, 18 esti-
mates in 13 countries (Belgium, Croatia, Czech
Republic, France, Germany, Greece, Hungary,
Ireland, Italy, the Netherlands, Romania, Slovakia
and Spain) were considered to be of higher quality
(score 54, Supplementary Table S9). These data are
presented in Figures 2 and 3. For Germany, Italy
and Spain, multiple higher quality estimates were
available and used to calculate a pooled estimate.
The HBsAg prevalence in the general population ran-
ged from 0·1% in Ireland [21] to 4·4% in Romania [22]
(Fig. 3). Eleven of the 13 estimates were around or
below 1%. Several higher quality prevalence estimates
were available for Italy which, when pooled, resulted
in an estimated HBV prevalence of 0·7%. There is,
however, wide heterogeneity among these single
study prevalence estimates from Italy, ranging from
0·5% (Apuglia, Southern Italy [23]) to 5·8%
(Bergamo, Northern Italy [24]).
Of the 45 anti-HCV prevalence estimates, 19 higher
quality (score 54, Supplementary Table S9) preva-
lence estimates from 13 countries (Belgium, Croatia,
France, Germany, Greece, Hungary, Ireland, Italy,
Latvia, the Netherlands, Romania, Slovakia and
Spain) were available. These data are presented in
Figures 2 and 4. Multiple higher quality estimates
were available for a pooled estimate in Germany
and Italy. The anti-HCV prevalence in the general
population ranged from 0·1% in Belgium [25],
Ireland [21] and the Netherlands [26] to 5·9% in
Italy (Fig. 4). Relatively high anti-HCV prevalence
was also found in Romania (3·2%) [27], Greece
(2·2%) [28], Latvia (2·4%) [29] and Slovakia (2·0%)
[30]. The estimate for Greece, however, is based on
a sample from the population of Crete [28]. Four esti-
mates were available for Spain, of which only one was
of higher quality and reported an anti-HCV preva-
lence of 1·1% [31]. The others ranged from 0·4% in
Barcelona [32] and 0·6% in Murcia and Madrid [33]
to 1·5% in multiple GP practices around Barcelona
[32].
Pregnant women
To estimate the prevalence in pregnant women, 27
HBsAg estimates from 11 countries (Supplementary
Table S10) and 15 anti-HCV estimates from eight
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countries (Supplementary Table S11) were retrieved
from 32 eligible studies. Multiple estimates were avail-
able for nine countries, with the highest number of
estimates (six) retrieved for Greece. Pooled estimates
were available for Denmark, Italy, the Netherlands
and the United Kingdom. Higher quality estimates
(score 52, Supplementary Table S12) of HBsAg
prevalence were available for seven countries, ranging
Fig. 1. Flow chart of study selection for the general population and pregnant women; EU/EEA countries, 2005–2015.
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from 0·1% in Norway [34] and Spain [35] to 0·8% in
France [36] and Italy (Fig. 3). For the Netherlands,
HBsAg prevalence in pregnant women increased
slightly from 0·3% in 2006 [37] and 2007 [37] to
0·4% in 2008 [37].
Of the 15 HCV estimates for pregnant women,
higher quality estimates (score 52, Supplementary
Table S12) were available for Slovenia, Spain, Italy
and Norway, with prevalence ranging from 0·1% in
Slovenia [38] to 0·9% in Norway [34] (Fig. 4). The esti-
mate for Slovenia is pooled, calculated using data
from 2003, 2009 and 2013, which indicates a slight
decrease in anti-HCV prevalence from 0·2% in 2003
to 0·1% in 2009 and 2013 [38].
First-time blood donors
The prevalence of HBsAg and anti-HCV in ﬁrst-time
blood donors was available for 30 countries (Table 1).
For Latvia and Portugal, the absolute number of
positive cases and ﬁrst-time blood donors were
unavailable, thus no 95% CI could be calculated.
The prevalence of chronic HBV infection among
ﬁrst-time blood donors ranged from 0·0% in Finland
and Luxembourg to 3·2% in Bulgaria. Most countries
(18/31, 58%) had an HBsAg prevalence that was
around or below 0·1%.
The prevalence of anti-HCV among ﬁrst-time blood
donors ranged from 0·0% in Iceland to 2·2% in Latvia,
and 58% of countries had an HCV prevalence that
was about or below 0·1%.
European HBV/HCV prevalence estimates
Using prevalence estimates for the general population
and blood donors, the HBsAg prevalence in the
EU/EEA as a whole is estimated to be 0·9%
(95% CI 0·7–1·2), equivalent to almost 4·7 million
chronic HBV cases. An overview of the estimated
prevalence and data used for each country is in
Supplementary Table S13. The United Kingdom has
the largest estimated burden of chronic HBV in the
EU/EEA with over a million cases, followed by
Romania (877 682), and Spain, France and Italy
(each with between 400 000 and 500 000 cases).
The anti-HCV prevalence in the EU/EEA is esti-
mated at 1·1% (95% CI 0·9–1·4) equivalent to
approximately 5·6 million anti-HCV-positive cases.
Of these, an estimated 70% are chronically infected,
i.e. viraemic replication with detectable HCV RNA
[17]. France, Italy, Poland, Romania, Spain and the
United Kingdom have the largest burden of chronic
HCV with between 350 000 and 2·5 million anti-
HCV-positive people.
DISCUSSION
In this review, we have compiled recent evidence avail-
able on the prevalence of chronic HBV and HCV
infection in the general population, pregnant women
and blood donors from EU/EEA countries to provide
further information on the epidemiology of these
infections and to identify gaps in the available
evidence.
Fig. 2. HBsAg prevalence (left) and anti-HCV prevalence (right) in the adult general population in the EU/EEA, based
on studies published between 2005 and 2015.
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Fig. 3. HBsAg prevalence estimates from studies with a lower risk of bias for the general population (study quality score
54) and for pregnant women (study quality score 52), in the EU/EEA, 2005–2015 (legend: country, prevalence estimate
(95% CI) and sample size (N), general population estimates represented by diamond data points, pregnant women
estimates represented in italics with triangle data points). *Standardized estimates were used for Belgium and Czech
Republic. *Pooled estimates were used for Germany, Italy and Spain for the general population and for Denmark, Italy,
the Netherlands and the UK for pregnant women.
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The prevalence of chronic HBV and HCV in the
general population varies widely across the 16 EU/
EEA countries for which estimates were available,
with a higher HBsAg and anti-HCV prevalence in
countries in the Eastern and Southern part of the
EU/EEA. There is great diversity across the region
and the estimated prevalence in the country with the
highest HBsAg estimate in the EU/EEA (Romania)
is 44 times higher than in the country with the lowest
estimated prevalence (Ireland). We also found that the
highest single estimated anti-HCV prevalence (in
Italy) is nearly 60 times higher than estimates from
countries with the lowest prevalence (Belgium,
Ireland and the Netherlands). Differing risk factors
and transmission routes might partially explain this
variation across countries, as well as different imple-
mentation of prevention and control strategies.
This study updates the previous ECDC systematic
review [18] and adds new estimates of HBsAg in the
general population for six countries (Germany,
Greece, Ireland, Italy, the Netherlands and
Romania). Although we did not conduct a statistical
analysis of differences between the reviews, there is
evidence of change over time in all countries except
Fig. 4. Anti-HCV prevalence estimates from studies with a lower risk of bias for the general population (study quality
score 54) and for pregnant women (study quality score 52), in the EU/EEA, 2005–2015 (legend: country, prevalence
estimate (95% CI) and sample size (N), general population estimates represented by diamond data points, pregnant
women estimates in italics with triangle data points). *Pooled estimates were used for Germany and Italy.
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Ireland. A decline in HBV prevalence was observed in
Germany (0·6–0·4%) and Romania (5·6–4·4%).
Improved primary prevention programmes including
antenatal screening and HBV vaccination are likely
explanations for this decline, especially in Romania.
A decline in estimated prevalence is also likely for
Italy, but with only regional prevalence estimates
reported in 2009 (due to heterogeneity across North,
Central and South Italy), we cannot compare the
pooled 0·8% HBsAg prevalence estimate derived
from the samples included in this study. This study
also observed heterogeneity in the estimates for Italy
derived from higher quality studies (0·5–5·8%). An
increase in estimated prevalence was observed in
Greece (2·1–3·3%) and the Netherlands (0·1–0·2%).
Limited geographical coverage is a likely explanation
for the increase in Greece as neither estimate is from a
national sample (the 2009 study covered the
Peloponnesus [39]; the study in this review was con-
ducted in Crete [28]). The slight increase in the
Netherlands can be explained by the increase of the
migrant population in the country, as was reported
in the original study [40].
New high-quality anti-HCV prevalence estimates
were available for ﬁve countries (France, Germany,
Greece, the Netherlands and Spain). Again, although
no statistical testing was conducted, results suggest
that while the chronic HCV prevalence remained at
0·4% in Germany, it declined over time in France,
the Netherlands and Spain, and increased in Greece.
As with HBsAg prevalence, it is possible that the
increase in Greece is mostly a reﬂection of the
restricted geographical coverage of both the current
estimate (Crete [28]) and the two reported in 2009
Table 1. Prevalence of HBsAg and anti-HCV in ﬁrst-time blood donors, EU/EEA*
Country Prevalence of HBsAg (95% CI) Prevalence of anti-HCV (95% CI) Council of Europe Report
Austria 0·099% (0·072–0·132) 0·039% (0·023–0·061) 2010
Belgium 0·077% (0·055–0·104) 0·039% (0·024–0·060) 2011
Bulgaria 3·224% (3·039–3·418) 0·342% (0·282–0·410) 2011
Croatia 0·233% (0·142–0·359) 0·140% (0·072–0·244) 2011
Republic of Cyprus 0·441% (0·270–0·681) 0·221% (0·106–0·405) 2008
Czech Republic 0·059% (0·040–0·085) 0·216% (0·177–0·261) 2011
Denmark 0·016% (0·004–0·040) 0·016% (0·004–0·040) 2011
Estonia 0·267% (0·128–0·490) 0·959% (0·673–1·326) 2011
Finland 0·000% (0·000–0·019) 0·025% (0·008–0·059) 2011
France 0·070% (0·062–0·079) 0·034% (0·028–0·040) 2011
Germany 0·116% (0·107–0·126) 0·062% (0·055–0·069) 2011
Greece 1·374% (1·280–1·473) 1·202% (1·114–1·295) 2011
Hungary 0·009% (0·003–0·021) 0·159% (0·128–0·195) 2011
Iceland 0·072% (0·002–0·398) 0·000% (0·000–0·264) 2011
Ireland 0·039% (0·013–0·090) 0·008% (0·000–0·043) 2011
Italy 0·168% (0·155–0·181) 0·094% (0·085–0·104) 2011
Latvia† 1·127% 2·170% 2003
Liechtenstein – – n/a
Lithuania 0·560% (0·468–0·665) 1·537% (1·382–1·704) 2011
Luxembourg 0·000% (0·000–0·406) 0·221% (0·027–0·794) 2011
Malta 0·174% (0·047–0·445) 0·043% (0·001–0·242) 2011
The Netherlands 0·034% (0·018–0·060) 0·020% (0·008–0·041) 2011
Norway 0·028% (0·009–0·065) 0·033% (0·012–0·073) 2011
Poland 0·450% (0·425–0·476) 0·742% (0·710–0·775) 2010
Portugal 0·094% 0·165% 2006
Romania 3·078% (2·965–3·195) 0·590% (0·541–0·643) 2011
Slovakia 0·072% (0·048–0·104) 0·025% (0·012–0·046) 2011
Slovenia 0·087% (0·043–0·155) 0·016% (0·002–0·057) 2009
Spain 0·168% (0·152–0·185) 0·099% (0·086–0·112) 2011
Sweden 0·043% (0·026–0·065) 0·059% (0·040–0·085) 2009
United Kingdom 0·038% (0·030–0·047) 0·037% (0·030–0·047) 2011
* Adapted from Table 1 and 7·1, Council of Europe Report 2014 [20].
†Latvia: no data are available after 2003.
Chronic HBV/HCV prevalence in the EU/EEA 2881
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268817001947
Downloaded from https://www.cambridge.org/core. Erasmus MC Rotterdam, on 25 Sep 2018 at 13:25:47, subject to the Cambridge Core terms of use, available at
(Peloponnesus [39] and Zakynthos [41]). The new esti-
mates for France and the Netherlands are derived
from large-scale national random samples, whereas
in 2009, the estimates were derived from regional/city-
speciﬁc estimates where higher risk populations are
over-represented. New estimates not previously avail-
able in 2009 were available for Hungary, Ireland,
Croatia (not in the EU/EEA in 2009) and Latvia.
Both Ott et al. [42] and Schweitzer et al. [7] found
that HBsAg prevalence increases eastwards across
the EU/EEA; Schweitzer et al. reports the highest esti-
mated prevalence found in Romania. While most
HBsAg prevalence estimates are comparable, there
are some notably different estimates reported by
Schweitzer et al. for the 1990–2015 period, particu-
larly for Greece (0·97% vs. 3·3% in this review) and
the United Kingdom (0·01% vs. 1·74% in this review).
Methodological differences, speciﬁcally the inclusion
of a wider timeframe and a broader deﬁnition of the
general population to include blood donors, pregnant
women and health care workers, could explain these
differences.
For anti-HCV, an increase in Eastern and Southern
EU countries was also reported. Similar to the
ﬁndings from this review, Gower et al. found the high-
est prevalence estimates for Romania (3·2%),
Lithuania (2·9%) and Latvia (2·4%) [43]. However,
there is some divergence in the reported estimates
for Italy. Our pooled 5·9% prevalence is considerably
higher than the published 2·2% [43], yet the wide
‘uncertainty range’ (notably not a CI) reported by
Gower et al. does include 5·6%, suggesting some com-
parability. In our study, 14 highly heterogeneous esti-
mates (0·6% [44] to 27·6% [45]) met the inclusion
criteria, four of which were pooled. Gower et al., how-
ever, selected one ‘best estimate’ to represent a coun-
try. Ultimately, our ﬁndings suggest that the
prevalence in Gower et al. could be an underestimate;
on the other hand, our estimate for Italy might be
skewed upwards by included studies conducted in
remote areas of the centre of the country.
HCV estimates presented in Cornberg et al. for
France, Germany, Hungary and Romania were very
similar to the estimates in this paper or the same
study was identiﬁed as the most reliable estimate
[46, 47]. Cornberg et al. suggest that the best preva-
lence estimate for Italy is 4·4% (all ages) and 5·2%
for adults, similar to the 5·9% we found. Cornberg
et al. most diverges with our ﬁndings for Spain
(2·6% vs. 1·1% in this review) [31]. Although they
also present other estimates they conclude, along
with Esteban et al., that the prevalence in Spain is
around 2·5% [48], suggesting our ﬁndings may be an
underestimate of the true prevalence in the country.
The differences in prevalence between countries and
over time are difﬁcult to interpret, because compar-
ability between studies is limited by the use of different
study designs, probabilistic and non-probabilistic
sampling strategies, and use of different laboratory
tests and sample types. In addition, geographical
representativeness is limited as most studies were per-
formed at sub-national level. Representative sero-
prevalence studies for the general population are
thus needed for valid comparison.
Pregnant women
Pregnant women are commonly considered as proxy
for the general population, albeit to a different extent
for HBV and HCV. The majority of EU/EEA MS
offer antenatal HBV screening. Estimates of HBsAg
prevalence among pregnant women, although slightly
higher, mostly align with observed general population
estimates in most countries, except in Greece and
Spain, where the prevalence among pregnant women
is lower. This is consistent with results of the 2009 sys-
tematic review [18]. The prevalence data for pregnant
women in Spain are more recent than the general
population estimates, so the difference between these
groups might reﬂect a change in prevalence over
time. For Greece, the prevalence data for pregnant
women are from a national sample, while the general
population data are derived from a regional sample.
While a lower HBV prevalence could be expected in
pregnant women, based on gender and age differ-
ences, groups with a higher risk of chronic viral hepa-
titis, such as migrants, are often under-represented in
general population studies and may possibly be over-
represented among samples in pregnant women.
Anti-HCV prevalence in pregnant women, where
available for comparison with higher quality general
population estimates, was found to be considerably
lower. Chronic HCV infections in many EU/EEA
countries have an age- and gender-speciﬁc prevalence
distribution, with some studies from Southern Europe
suggesting that 60% of the infected population is over
65 years of age [46]. Older and male populations,
mostly infected through injecting drug use, contami-
nated blood or blood products, or improper infection
control practices in health care, are not represented in
studies in pregnant women [46], and our ﬁndings sug-
gest that pregnant women are not a reliable proxy
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population to estimate prevalence in the general
population.
First-time blood donors
HBV and HCV seroprevalence data in ﬁrst-time blood
donors are readily available for most EU/EEA coun-
tries and are the most complete population prevalence
source. Although blood donors are often used as a
proxy population, this subgroup is generally consid-
ered not to be a representative sample due to self-
selection of blood donors and strict regulation by
blood banks [49]. These selection biases are reﬂected
in our ﬁndings, which show that prevalence in
ﬁrst-time blood donors is considerably lower than gen-
eral population estimates for all countries, although
some conﬁdence intervals overlap. Latvia may be
the notable exception with a reported anti-HCV sero-
prevalence of 2·2% among ﬁrst-time blood donors in
2003 (the latest estimate available), largely compar-
able with the higher quality estimate of 2·4% in 2008
in the general population [29].
The burden of chronic hepatitis B and C in the EU/EEA
The HBV and HCV prevalence in the EU/EEA as a
whole is estimated to be around 0·9% and 1·1%,
respectively, resulting in an estimated total of 4·7
million chronic HBV cases and 5·6 million anti-
HCV-positive cases. Considering that an estimated
70% of anti-HCV-positive cases are chronically
infected [17], this corresponds with approximately
3·9 million chronic HCV cases.
The robustness of these ﬁgures is inﬂuenced not
only by the intrinsic limitation of using prevalence
estimates derived from an array of diverse studies,
but also by the inclusion of prevalence estimates
among blood donors as a proxy for the general popu-
lation in the absence of other evidence. However,
when taking into account both HBV and HCV data,
general population estimates obtained from included
studies accounted for approximately 83% of the total
European population, with the remaining 17% cov-
ered by blood donor estimates.
Other than perhaps the population size of the coun-
try, no clear distribution across the EU can be
observed in the availability of (higher quality) esti-
mates in any of the targeted population groups. For
one country, Liechtenstein, no information about
HBV and HCV prevalence was available for any of
the population groups. For Cyprus, Iceland and
Malta, only prevalence data on ﬁrst-time blood
donors were available, and for Austria, Estonia,
Lithuania, Poland and Sweden, only low-quality esti-
mates were available.
Strengths and limitations
An important strength of this review is that publica-
tions in all EU/EEA languages were included. In add-
ition, consultation with MS further supplemented and
validated the evidence retrieved. We feel that the
lower sensitivity in the literature search due to the
use of a geographical ﬁlter was effectively offset by
the MS consultations. Another strength is that small-
sample studies were excluded, a risk of bias assessment
was developed and applied, and only high-quality esti-
mates were selected and pooled (if multiple were avail-
able) for the analyses, to ease inter- and intra-country
comparisons. The risk of bias assessment tool, how-
ever, has not been previously tested. An untested
assumption in the tool is the equal weight given to
each domain to calculate a ﬁnal quality rating. For
ﬁrst-time blood donors, another data source was
used rather than studies identiﬁed via a systematic
review and the source was not assessed for bias.
This systematic literature review conﬁrms the diver-
sity in prevalence of chronic HBV and HCV infections
across the EU/EEA, as well as the variability between
groups often considered to provide a good proxy for
the general population. Our ﬁndings suggest that
using blood donor or pregnant women data as a
proxy for HCV and, to a certain extent, HBV preva-
lence estimates for the general population is not desir-
able. Comparing to other regions globally, HBV and
HCV prevalence in the EU/EEA is low, with some
sign of decline, at least for HBV. The availability of
studies with relatively recent data on the prevalence
in the general population is limited, with data for
around half of the 31 countries in the EU/EEA,
reporting higher HBV and HCV prevalence in coun-
tries in the Eastern and Southern part of the region.
The epidemiology of HBV and HCV is constantly
changing, in part due to the impact of prevention
and control programmes and changes in risk factors,
but many countries lack recent robust epidemiological
studies that provide reliable estimates of the burden of
chronic viral hepatitis. The lack of high-quality,
recent, nationwide prevalence estimates and the het-
erogeneity of available studies makes it challenging
to gain an EU/EEA overview of the current epidemio-
logical situation regarding chronic viral hepatitis. The
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need for high-quality strategic information on the bur-
den of HBV and HCV is compelling, not only for scal-
ing up secondary prevention services appropriately,
but also to inform regional and global activities that
will shape the response to these epidemics in years
to come. This could be achieved by complementing
case-based surveillance with alternative data sources
with adequate standardization levels across the region.
A standardized seroprevalence survey performed
across the EU/EEA, while resource intensive, may
be a well-needed intervention to consider.
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